Novel alpha radiopharmaceutical therapy shows promise in early-phase prostate cancer trial
A new alpha-emitting radiopharmaceutical therapy (RPT) for advanced prostate cancer was well tolerated, with no dose-limiting toxicities observed, and showed encouraging signs of antitumor activity, according to a trial published in The Journal of Nuclear Medicine's Late-Breaking Fast Track.
Read original article on Medical Xpress - latest medical and health news stories →Related news
-
Workplace ergonomics may do little to ease arm, neck or shoulder pain
Health
Medicine
-
Needle-free Strep A vaccine triggers local and bodywide immune responses in mice
Health
Disease & Outbreaks
-
Wearable EEG patch records stable brain signals over 24 hours, including sleep
Science
Research
-
How socioeconomic factors affect outcomes in this deadly cancer
Health
Disease & Outbreaks
United States
-
Autistic women experience more severe menopausal symptoms, study confirms
Health
Medicine
-
Q&A: Could a new melanoma vaccine change cancer treatment?
Health
Medicine
-
ADHD medication amplifies brain response to grammatically ambiguous sentences, study finds
Science
Research
Netherlands
-
Night shifts during pregnancy linked to heightened risk of young child's neurodevelopmental abnormalities
Health
Public Health